OAC
TSHA icon

OMERS Administration Corp’s Taysha Gene Therapies TSHA Stock Holding History

OMERS Administration Corp’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$402K Buy
+59,100
New +$350K ﹤0.01% 814
2025
Q3 		– Sell
-72,900
Closed -$168K – 1215
2025
Q2 		$168K Buy
+72,900
New +$158K ﹤0.01% 793
2024
Q2 		– Sell
-28,000
Closed -$80.4K – 1212
2024
Q1 		$80.4K Buy
+28,000
New +$58.3K ﹤0.01% 344

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OMERS Administration Corp's TSHA Position: Q2 2026 in Review

OMERS Administration Corp opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 59,100 shares worth $402K. The stake represents ﹤0.01% of the portfolio and ranks #814 among its holdings. This is a return to the name: OMERS Administration Corp previously reported a position in TSHA as recently as Q2 2025.

OMERS Administration Corp first reported a position in TSHA in Q1 2024 and has held it in 3 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • OMERS Administration Corp held 59,100 shares of Taysha Gene Therapies worth $402K as of Q2 2026.
  • Taysha Gene Therapies was a new OMERS Administration Corp position in Q2 2026.
  • Taysha Gene Therapies made up ﹤0.01% of OMERS Administration Corp's portfolio in Q2 2026, its #814 holding.
  • OMERS Administration Corp first reported a position in Taysha Gene Therapies in Q1 2024 and has held it in 3 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on OMERS Administration Corp's 13F filing for Q2 2026, filed 13 Aug 2026.